Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature

Yang,Dan; Fu,Xiaorui; Zhang,Xudong; Li,Wencai; Zhang,Mingzhi

doi:10.3892/ol.2015.3703

Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature

Authors:
- Dan Yang
- Xiaorui Fu
- Xudong Zhang
- Wencai Li
- Mingzhi Zhang
View Affiliations

Affiliations: Lymphoma Diagnosis and Treatment Center, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: September 15, 2015 https://doi.org/10.3892/ol.2015.3703
Pages: 3261-3265

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to advances in the treatment of lymphoma, the remission and overall survival rates for this disease have improved in recent years. However, the incidence of therapy‑related myelodysplastic syndrome/acute myeloid leukemia (t‑MDS/AML) has increased. In order to further the understanding of the mechanisms of t‑MDS/AML and reduce its incidence, the present study reports 4 cases of t‑AML following treatment for lymphoma. The 4 patients presented aggressive forms of lymphoma in stage III/IV, and 3 were diagnosed with non‑Hodgkin's lymphoma. All patients had previously undergone chemotherapy containing alkylating agents and/or topoisomerase II inhibitors. The latency period between the time of primary diagnosis and occurrence of t‑AML ranged from 15 to 42 months. At the time of diagnosis of t‑AML, 3 of the 4 patients presented pancytopenia, whilst the remaining patient exhibited leukocytosis. The majority of the patients succumbed to their disease within 1 year of t‑AML diagnosis, with the exception of the patient in case 3, who survived following allogeneic hematopoietic stem cell transplantation (allo‑HSCT). The present cases indicate that an advanced stage of disease at the time of primary diagnosis, prior exposure to radiotherapy, and administration of ≥4 regimens and ≥8 cycles of chemotherapy may be risk factors for the development of t‑AML. Based on the present findings and a review of the literature, we propose that allo‑HSCT should be recommended for patients at high risk of developing t‑AML. In addition, chimeric antigen receptor T‑cell immunotherapy may constitute a novel type of immunotherapy for the treatment of cancer, particularly for cases of relapsed and refractory lymphoma or leukemia.

View Figures

View References

1	Allan JM and Travis LB: Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer. 5:943–955. 2005. View Article : Google Scholar : PubMed/NCBI
2	Seedhouse C and Russell N: Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol. 137:513–529. 2007. View Article : Google Scholar : PubMed/NCBI
3	Steinberg MH, Geary CG and Crosby WH: Acute granulocytic leukemia complicating Hodgkin's disease. Arch Intern Med. 125:496–498. 1970. View Article : Google Scholar : PubMed/NCBI
4	Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A and Bloomfield CD: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM, Larson RA, Allan JM and Onel K: MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood. 112:741–749. 2008. View Article : Google Scholar : PubMed/NCBI
6	Sabattini E, Bacci F, Sagramoso C and Pileri SA: WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview. Pathologica. 102:83–87. 2010.PubMed/NCBI
7	Huh HJ, Lee SH, Yoo KH, Sung KW, Koo HH, Kim K, Jang JH, Jung C, Kim SH and Kim HJ: Therapy-related myeloid neoplasms in 39 Korean patients: A single institution experience. Ann Lab Med. 33:97–104. 2013. View Article : Google Scholar : PubMed/NCBI
8	Schoch C, Kern W, Schnittger S, Hiddemann W and Haferlach T: Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 18:120–125. 2004. View Article : Google Scholar : PubMed/NCBI
9	Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 103:620–625. 1985. View Article : Google Scholar : PubMed/NCBI
10	Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, et al: German-Austrian AMLSG: The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 117:2137–2145. 2011. View Article : Google Scholar : PubMed/NCBI
11	Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD and Larson RA: Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 102:43–52. 2003. View Article : Google Scholar : PubMed/NCBI
12	Perera FP: Environment and cancer: who are susceptible? Science. 278:1068–1073. 1997. View Article : Google Scholar : PubMed/NCBI
13	Park DJ and Koeffler HP: Therapy-related myelodysplastic syndromes. Semin Hematol. 33:256–273. 1996.PubMed/NCBI
14	Pagana L, Pulsoni A, Tosti ME, Avvisati G, Mele L, Mele M, Martino B, Visani G, Cerri R, Di Bona E, et al: Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto: Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol. 112:109–117. 2001. View Article : Google Scholar : PubMed/NCBI
15	Hake CR, Graubert TA and Fenske TS: Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant. 39:59–70. 2007. View Article : Google Scholar : PubMed/NCBI
16	Bloomfield CD, Archer KJ, Mrózek K, Lillington DM, Kaneko Y, Head DR, Dal Cin P and Raimondi SC: 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: Report from an international workshop. Genes Chromosomes Cancer. 33:362–378. 2002. View Article : Google Scholar : PubMed/NCBI
17	Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM and Rowley JD: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes. (5 and 7)J Clin Oncol. 4:325–345. 1986.PubMed/NCBI
18	Uppal GK, Leighton J, Da Costa D, Czulewicz A and Palazzo IE: Therapy related acute myeloid leukemia with t(10:16): A rare entity. Hematol Rep. 3:e232011. View Article : Google Scholar : PubMed/NCBI
19	Pedersen-Bjergaard J: Insights into leukemogenesis from therapy-related leukemia. N Engl J Med. 352:1591–1594. 2005. View Article : Google Scholar : PubMed/NCBI
20	Pedersen-Bjergaard J, Specht L, Larsen SO, Ersbøll J, Struck J, Hansen MM, Hansen HH and Nissen NI: Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 2:83–88. 1987. View Article : Google Scholar : PubMed/NCBI
21	Godley LA and Larson RA: Therapy-related myeloid leukemia. Semin Oncol. 35:418–429. 2008. View Article : Google Scholar : PubMed/NCBI
22	Borthakur G and Estey AE: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep. 9:373–377. 2007. View Article : Google Scholar : PubMed/NCBI
23	Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J, Clark T, Foran JM, Salam A, Lister TA and Rohatiner AZ: Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 18:947–955. 2000.PubMed/NCBI
24	Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA, Matthews J, Foot NJ, Young BD, Lister TA and Rohatiner AZ: Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol. 19:2472–2481. 2001.PubMed/NCBI
25	Leone G, Pagano L, Ben-Yehuda D and Voso MT: Therapy-related leukemia and myelodysplasia: Susceptibility and incidence. Haematologica. 92:1389–1398. 2007. View Article : Google Scholar : PubMed/NCBI
26	Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM and Kroll S: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 21:897–906. 2003. View Article : Google Scholar : PubMed/NCBI
27	Milligan DW Ruiz, De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ, Colombat P and Schmitz N: European Group for Blood and Marrow Transplantation: Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol. 106:1020–1026. 1999. View Article : Google Scholar : PubMed/NCBI
28	Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG and Tarantolo SR: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 12:2527–2534. 1994.PubMed/NCBI
29	Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S, Fay JW, Freytes CO, Goldstein SC, Herzig RH, et al: Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study. Blood. 101:2015–2023. 2003. View Article : Google Scholar : PubMed/NCBI
30	Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM and Freedman AS: Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 23:2208–2214. 2005. View Article : Google Scholar : PubMed/NCBI
31	Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P and Freedman AS: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 12:2535–2542. 1994.PubMed/NCBI
32	Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M and Hiddemann W: Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol. 22:4926–4933. 2004. View Article : Google Scholar : PubMed/NCBI
33	Pulsoni A, Pagano L, Lo Coco F, Avvisati G, Mele L, Di Bona E, Invernizzi R, Leoni F, Marmont F, Mele A, et al: Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: The GIMEMA experience. Blood. 100:1972–1976. 2002. View Article : Google Scholar : PubMed/NCBI
34	Mrózek K, Heerema NA and Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev. 18:115–136. 2004. View Article : Google Scholar : PubMed/NCBI
35	Schlenk RF and Döhner K: Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol. 16:98–104. 2009. View Article : Google Scholar : PubMed/NCBI
36	Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E and Bolwell B: Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol. 24:3604–3610. 2006. View Article : Google Scholar : PubMed/NCBI
37	Eichenauer DA and Engert A: Therapy-related myeloid neoplasms in patients treated for Hodgkin's lymphoma. Mediterr J Hematol Infect Dis. 3:e20110462011. View Article : Google Scholar : PubMed/NCBI
38	Ogami A, Morimoto A, Hibi S, Todo S, Sugimoto T, Mori K, Imamura T, Ishida H, Yoshihara T, Iguchi A, et al: Secondary acute promyelocytic leukemia following chemotherapy for non-Hodgkin's lymphoma in a child. J Pediatr Hematol Oncol. 26:427–430. 2004. View Article : Google Scholar : PubMed/NCBI
39	Yuan SZ and Su H: Clinical translational research of chimeric antigen receptor-T (CAR-T) cells for the treatment of relapsed and refractory B-cell lymphoma/leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 22:1137–1141. 2014.(In Chinese). PubMed/NCBI
40	Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, Wang LL and Han WD: Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 23:184–191. 2015. View Article : Google Scholar : PubMed/NCBI
41	DeFrancesco L: CAR-T cell therapy seeks strategies to harness cytokine storm. Nat Biotechnol. 32:6042014. View Article : Google Scholar : PubMed/NCBI